IND Filing
FDA
Clinical Trials
Clinical Development
Around the World
100

What does the three-letter acronym, used for a new drug test/existing drug that is being used to support a new indication, significant labeling change, or other major change in use stand for.

Investigational New Drug

100

What does the three-letter federal agency that regulates drugs, biologics, and medical devices in the United States stand for.


Federal Drug Administration (FDA)


100

Number of clinical trials needed to approve a therapetic product

4 

100

This acronym stands for Good Manufacturing Practice


GMP

100

A company has an active U.S. IND and wants to begin a clinical trial in Denmark. Can it proceed using only its U.S. IND?

No - it must be receive authorization  in Denmark through the EU clinical trial framework. 

200

3 types of information present in every IND.

- Preclinical data

- Manufacturing data

- Clinical protocol and investigator qualifications

200

This FDA center is primarily responsible for regulating human drugs.


CDER (Center for Drug Evaluation and Research)

200

This document explains study risks and procedures to participants before they voluntarily agree to participate.

Informed consent

200

This type of study compares an investigational treatment with an inactive substance that looks like the treatment.

Placebo controlled study

200

Operation Trialblazer has this type of pre-IND review submission 

Rolling
300

Type of IND study used for unapproved drug or approved drug in new patient population

Investigator IND

300

Recently launched U.S Department of Health and Human Services imitative supported by the FDA program to accelerate early stage clinical development through measures such as expedited IND pilot program, clarified Phase 1 CMC requirements, etc. 

FDA TrialBlazer

300

This term describes an unfavorable medical occurrence in a clinical trial participant, whether or not it is caused by the investigational drug.

Adverse effect (AE)

300

This term describes the length of time a drug product is expected to remain within established specifications when stored under defined conditions.

Shelf life

300

The FAST-EU regulatory integrates the FDA and what other agency.

IRB

400

The regulatory requirements for INDs are defined covering scope, definitions, content, safety reporting, amendments, and investigator responsibilities in the CFR

 21 CFR Part 312

400

This is the type of FDA action that delays or suspends a proposed or ongoing clinical investigation.


Clinical hold

400

This document describes the planned methods for analyzing clinical trial data, including endpoints and statistical tests.

Statistical Analysis Plan (SAP)

400

This term describes the amount of product produced during a manufacturing run.


Batch yield

400

Australias CTN (Clinical Trial Notification) scheme is an ethics-based regulatory scheme governed by which Australian ethics committee.

Human Research Ethics Committee (HREC)

500

How many days an IND becomes effective after approval from FDA

30 days

500

How many days an IND becomes effective after approval from FDA

30 days

500

This clinical trial phase typically provides initial evidence of effectiveness and continues evaluating safety in patients with the condition.

Phase 2

500

Under 21 CFR 312.38, this regulatory action ends all clinical investigations under an IND and generally requires a final report.

IND withdrawal

500

First in Human Trials in this East Asian country has a recognized investigator issued trial (IIT) framework

Japan